Gentium price target raised to $24 from $21 at Brean Capital Brean Capital raised its price target on Gentium following Q2 results. The firm cited the expected EU launch and increased pricing of Defitelio in Q4 as well as the potential for the increase in global sales for Defibrotide. Shares are Buy rated.
News For GENT From The Last 14 Days
Check below for free stories on GENT the last two weeks.